ESC 365 - Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

ESC Professional Premium Access

Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Session: Heart failure: drug therapy and multidisciplinary care

Topic: Pharmacotherapy

Speaker: Doctor S. Matsumoto (Tokyo, JP)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Shingo Matsumoto

Toho University, Tokyo (Japan)

0 follower

6 more presentations in this session

Systematic review and meta-analysis on the effects of physical activity-based interventions on frailty status and clinical outcomes in adults with long-term cardiac conditions.

Speaker: Ms H. Waterhouse (Leicester, GB)

Assessing the practicality of a novel heart failure therapeutic score (QUAD Score) for drug optimisation in heart failure with a reduced ejection fraction

Speaker: Doctor A. Ganapathy (Basildon, GB)

Short-term effects on sacubitril/valsartan therapy on right ventricle work and mechanics in patients with heart failure and reduced ejection fraction

Speaker: Doctor J. Ottela (Turku, FI)

Cardiovascular mortality with oral potassium-binders in patients with CKD and heart failure

Speaker: Doctor H. Barzkar (Dallas, US)

The effects of angiotensin receptor-neprilysin inhibitors on clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: real-world evidence from the CCA Database-HF Center

Speaker: Doctor Z. Xie (Shanghai, CN) Professor J. Zhou (Shanghai, CN)

Access the full session

Heart failure: drug therapy and multidisciplinary care

Speakers: Doctor S. Matsumoto, Ms H. Waterhouse, Doctor A. Ganapathy, Doctor J. Ottela, Doctor H. Barzkar...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources